Company
Changsha Biovision Software Technology Co., Ltd. (Biovision Software) was founded in 2009, established in the Changsha High-tech Zone as a government-introduced programme bringing international talent and technology to Hunan. The company develops medical IT and clinical AI products, with more than 50 products in-house across four lines: medical imaging, ECG networks, regional healthcare platforms and clinical AI.
Per the company’s public statements, its systems run in over 4,000 healthcare institutions, and it has built more than 80 municipal and county-level regional healthcare platforms, covering Hunan, Shanghai, Hubei, Guangxi, Yunnan, Sichuan, Hebei and Guizhou.
Milestones
- 2009 — Company founded in Changsha High-tech Zone as a government-introduced international talent and technology programme.
- 2010 — R&D cooperation agreement with Peking University Graduate School; medical device manufacturing and product registration qualifications obtained.
- 2013 — R&D team selected for Changsha’s “313” overseas high-end talent programme; launched a 3D medical image reconstruction and analysis system with organ quantification.
- 2016 — Listed on the NEEQ (New Third Board); 101 heterogeneous data acquisition technology developed to break medical information silos; medical big-data platform released.
- 2017 — Winner of the China International Big Data Mining Competition at the Big Data Expo.
- 2018 — Cooperation agreements with Nanhai District (Foshan) and Gui’an New Area; Xiaobang medical software robot launched.
- 2019 — “Demonstration Application Scenario” award at the Hunan AI Industry Innovation and Application Competition; named among the first batch of key AI enterprises in Hunan; cloud imaging product launched.
- 2020 — “Flagship Innovative Product” award at the same competition; listed in Hunan’s two-type product government procurement catalogue.
- 2021 — Strategic cooperation agreement with Zhongneng Group in smart city; participation in the Ministry of Science and Technology clinical diagnosis and treatment platform project.
- 2022–2023 — “Key technologies and products of RPA robotic process automation” received the Hunan Provincial Technological Invention Award, third prize.
Four business lines
- Medical imaging: enterprise PACS with 3D and AI, radiology, ultrasound, endoscopy, dental, pathology, nuclear medicine, imaging QC, clinical scheduling, 3D AI viewing, electronic film / cloud film, and an imaging AI research platform.
- ECG networks: hospital-wide ECG network and electrophysiology network with automatic measurement, diagnostic suggestions and critical-value alerts.
- Regional healthcare: city-level medical AI brain, medical consortium platform, regional PACS / LIS / ECG, result mutual recognition, tele-radiology / ultrasound / pathology consultation, tele-clinic, two-way referral and tele-education.
- Clinical AI and automation: clinical decision support (CDSS), EMR AI quality control, and the Xiaobang RPA robot for cross-system data acquisition.
R&D and IP
Biovision is a recognised High-tech Enterprise, with more than 50 patent applications and over 40 software copyrights per public disclosure. Its in-house 101 heterogeneous data acquisition technology addresses the multi-vendor data silos typical of Chinese hospitals and serves as the data foundation for regional platforms and AI applications.
Quality and compliance
The company holds medical device manufacturing and product registration qualifications, and several products are listed in Hunan’s two-type product government procurement catalogue. Registration numbers, validity and scope of application, as well as supporting material for cybersecurity grading and interoperability assessments, are available on request.